October 7, 2025 — Leads & Copy —
Bayer AG and BlueRock Therapeutics LP announced positive 36-month data from the exPDite Phase I clinical trial of bemdaneprocel, an investigational cell therapy for Parkinson’s disease (PD). The data, presented at the International Congress of Parkinson’s Disease and Movements Disorders on October 6th, show bemdaneprocel is well tolerated with positive trends in motor symptom improvement.
The safety profile of bemdaneprocel at 36 months remains consistent, with no adverse events reported related to the therapy or surgical procedure. F-Dopa imaging indicates continued survival and engraftment of transplanted cells in the brain after discontinuing immunosuppression therapy at 12 months. Secondary clinical endpoints show positive trends in motor symptoms from baseline, particularly in the high-dose cohort, as assessed by the MDS-UPDRS Part II & III and the Parkinson’s disease Diary.
In the high-dose cohort (n=7), the MDS-UPDRS Part III measurement showed a mean reduction of 17.9 points compared to baseline. The low-dose cohort (N=4) showed a mean decrease of 13.5 points. Using the PD Diary, high-dose cohort participants showed a mean increase of 1 hour in time spent in the “Good ON” state compared to baseline after 36 months. The 36-month measurement of activities of daily living using the MDS-UPDRS Part II in the high-dose cohort showed a mean reduction of -4.3 points compared to baseline.
Christian Rommel, Global Head of Research and Development of the Pharmaceuticals Division at Bayer, stated that the results reinforce the company’s commitment to developing new treatment options for Parkinson’s patients.
Gabi Belfort, MD, PhD, Senior Vice President and Bemdaneprocel Product Lead at BlueRock Therapeutics.
For more information, visit www.bluerocktx.com.
Source: Bayer
